Ripal T. Gandhi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ripal T. Gandhi has a total of 225 co-authors. Here are the top co-authors by number of shared publications:
Alex Powell
4 shared publicationsBrian Schiro
Miami Cardiac & Vasc Inst, Dept Intervent Radiol, 8900 North Kendall Dr, Kendall, FL 33176 USA
4 shared publicationsGovindarajan Narayanan
Department of Interventional Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, Florida, United States
4 shared publications- Madelon Dijkstra
Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, 2333 ZG Amsterdam, The Netherlands
4 shared publications - Wissam A. Jaber
Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
4 shared publications - Andrew S. Kennedy
Sarah Cannon Research Institute, Nashville, Tennessee
3 shared publications
Latest Publications
- 1 September 2026
- Published by Radiological Society of North America (RSNA) in Radiology: Imaging Cancer
- Vol. 8 (5)
Circulating Proteins for Pretreatment Risk Stratification in Image-guided Liver Therapy
- 1 September 2026
- Published by Radiological Society of North America (RSNA) in Radiology: Imaging Cancer
- Vol. 8 (5)
Circulating Proteins for Pretreatment Risk Stratification in Image-guided Liver Therapy
- Open Access
- 25 August 2026
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 5 (10) , 105578
Cost-Effectiveness of Large-Bore Mechanical Thrombectomy Versus Catheter-Directed Thrombolysis for Intermediate-Risk Pulmonary Embolism: A PEERLESS Randomized Controlled Trial Post Hoc Analysis
- 25 August 2026
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 5 (10) , 105578
Open AccessCost-Effectiveness of Large-Bore Mechanical Thrombectomy Versus Catheter-Directed Thrombolysis for Intermediate-Risk Pulmonary Embolism: A PEERLESS Randomized Controlled Trial Post Hoc Analysis
- Open Access
- 20 August 2026
- Published by Georg Thieme Verlag KG in Journal of Clinical Interventional Radiology ISVIR
A Retrospective Overview of Balloon Dissection to Prevent Gastrointestinal Injury During Thermal Ablation of Renal and Liver Tumors
The aim of this study was to assess balloon dissection as an adjunctive technique during percutaneous thermal ablation of renal and hepatic tumors near critical structures. In this retrospective study, patients underwent CT-guided percutaneous ablation under general anesthesia for tumors located ≤1 cm from critical structures. A Yueh needle was used to access the space between the tumor and the critical structure, followed by Bentson wire insertion and vascular sheath placement to position a balloon, which was then inflated to create separation. The primary objectives were feasibility, safety, and technical success. Feasibility was defined as successful balloon placement; safety as procedure-related adverse events; and technical success as complete ablation with a >5 mm margin on immediate post-procedure imaging. Twelve patients underwent image-guided percutaneous ablation of kidney and liver lesions. Balloon placement between the target tumor and the adjacent bowel was successful in all cases. Six patients (50%) received cryoablation for renal cell carcinoma (RCC), and six (50%) underwent microwave ablation (MWA) for hepatocellular carcinoma (HCC, n = 2), colorectal liver metastases (CRLM, n = 2), and RCC liver metastases (n = 2). Mean tumor size was 3.7 cm (SD, 1.5) for renal tumors and 3.0 cm (SD, 1.3) for hepatic tumors. Technical success with sufficient tumor margins was achieved in all cases, and no thermal injury to adjacent structures was observed. One grade 1 and two grade 2 complications occurred, unrelated to balloon insertion. Balloon dissection is a technically feasible and safe technique to facilitate thermal ablation of renal and hepatic tumors located in proximity to critical structures.
- 20 August 2026
- Published by Georg Thieme Verlag KG in Journal of Clinical Interventional Radiology ISVIR
Open AccessA Retrospective Overview of Balloon Dissection to Prevent Gastrointestinal Injury During Thermal Ablation of Renal and Liver Tumors
The aim of this study was to assess balloon dissection as an adjunctive technique during percutaneous thermal ablation of renal and hepatic tumors near critical structures. In this retrospective study, patients underwent CT-guided percutaneous ablation under general anesthesia for tumors located ≤1 cm from critical structures. A Yueh needle was used to access the space between the tumor and the critical structure, followed by Bentson wire insertion and vascular sheath placement to position a balloon, which was then inflated to create separation. The primary objectives were feasibility, safety, and technical success. Feasibility was defined as successful balloon placement; safety as procedure-related adverse events; and technical success as complete ablation with a >5 mm margin on immediate post-procedure imaging. Twelve patients underwent image-guided percutaneous ablation of kidney and liver lesions. Balloon placement between the target tumor and the adjacent bowel was successful in all cases. Six patients (50%) received cryoablation for renal cell carcinoma (RCC), and six (50%) underwent microwave ablation (MWA) for hepatocellular carcinoma (HCC, n = 2), colorectal liver metastases (CRLM, n = 2), and RCC liver metastases (n = 2). Mean tumor size was 3.7 cm (SD, 1.5) for renal tumors and 3.0 cm (SD, 1.3) for hepatic tumors. Technical success with sufficient tumor margins was achieved in all cases, and no thermal injury to adjacent structures was observed. One grade 1 and two grade 2 complications occurred, unrelated to balloon insertion. Balloon dissection is a technically feasible and safe technique to facilitate thermal ablation of renal and hepatic tumors located in proximity to critical structures.
- Open Access
- 7 March 2026
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 37 (6) , 108697
Robot-Assisted Microwave Ablations of Liver Tumors: Is This the Beginning of a Paradigm Shift?
- 7 March 2026
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 37 (6) , 108697
Open AccessRobot-Assisted Microwave Ablations of Liver Tumors: Is This the Beginning of a Paradigm Shift?
- 13 February 2026
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 37 (5) , 108591
In Vivo Evaluation of a Disposable Endovascular Robotic System for Arterial Peripheral Vascular Interventions: A Multicenter Feasibility Study
- 13 February 2026
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 37 (5) , 108591
In Vivo Evaluation of a Disposable Endovascular Robotic System for Arterial Peripheral Vascular Interventions: A Multicenter Feasibility Study
- Open Access
Clinical Efficacy of Percutaneous Image-Guided Ablation in Breast Cancer Metastases to the Liver
Objectives: This single-center retrospective study evaluates the clinical efficacy and safety of percutaneous ablation using microwave ablation (MWA) and irreversible electroporation (IRE) in patients with breast cancer liver metastases (BCLM). Methods: Between August 2018 and December 2023, 32 patients underwent 40 image-guided ablations for 57 BCLM. Mean age was 61.3 years (range: 32–85), and mean tumor size was 2.9 cm (range: 0.9–7.0 cm). Fifty lesions were treated with MWA and seven with IRE. Clinical efficacy was assessed by m-RECIST response at first follow-up imaging (after ≥1 month) and by monitoring local tumor progression (LTP), local tumor progression-free survival (LTPFS), and overall survival (OS). Safety was evaluated by adverse events according to CTCAE. Kaplan–Meier statistics were used for LTPFS and OS. Results: Median follow-up was 32.4 months (95% CI 16.6–48.0). Complete response was observed in 34 tumors (59.6%), partial response in 14 (24.6%), and progressive disease in 9 (15.8%). LTP occurred in 37 tumors (64.9%), with a median time to progression of 11.1 months (95% CI 1.4–20.8). One- and two-year LTPFS rates were 43.6% and 34.1%. Sixteen patients died during follow-up, with median OS of 27.8 months (95% CI 19.0–36.6) and 1- and 2-year OS rates of 90.1% and 55.9%. No major complications occurred. Complications included eight Grade 1 and two Grade 2 complications. Conclusions: Percutaneous ablation demonstrates clinical efficacy and a favorable safety profile in selected BCLM patients, achieving OS comparable to the current literature. Further studies should clarify its additive role within multimodality treatment.
Open AccessClinical Efficacy of Percutaneous Image-Guided Ablation in Breast Cancer Metastases to the Liver
Objectives: This single-center retrospective study evaluates the clinical efficacy and safety of percutaneous ablation using microwave ablation (MWA) and irreversible electroporation (IRE) in patients with breast cancer liver metastases (BCLM). Methods: Between August 2018 and December 2023, 32 patients underwent 40 image-guided ablations for 57 BCLM. Mean age was 61.3 years (range: 32–85), and mean tumor size was 2.9 cm (range: 0.9–7.0 cm). Fifty lesions were treated with MWA and seven with IRE. Clinical efficacy was assessed by m-RECIST response at first follow-up imaging (after ≥1 month) and by monitoring local tumor progression (LTP), local tumor progression-free survival (LTPFS), and overall survival (OS). Safety was evaluated by adverse events according to CTCAE. Kaplan–Meier statistics were used for LTPFS and OS. Results: Median follow-up was 32.4 months (95% CI 16.6–48.0). Complete response was observed in 34 tumors (59.6%), partial response in 14 (24.6%), and progressive disease in 9 (15.8%). LTP occurred in 37 tumors (64.9%), with a median time to progression of 11.1 months (95% CI 1.4–20.8). One- and two-year LTPFS rates were 43.6% and 34.1%. Sixteen patients died during follow-up, with median OS of 27.8 months (95% CI 19.0–36.6) and 1- and 2-year OS rates of 90.1% and 55.9%. No major complications occurred. Complications included eight Grade 1 and two Grade 2 complications. Conclusions: Percutaneous ablation demonstrates clinical efficacy and a favorable safety profile in selected BCLM patients, achieving OS comparable to the current literature. Further studies should clarify its additive role within multimodality treatment.
- Open Access
- 9 October 2025
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 37 (1) , 107866
Evaluation of Catheter-Directed Thrombolysis Device Type and Dosing on Treatment Outcomes in Intermediate-Risk Pulmonary Embolism: A PEERLESS Randomized Controlled Trial Post Hoc Analysis
- 9 October 2025
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 37 (1) , 107866
Open AccessEvaluation of Catheter-Directed Thrombolysis Device Type and Dosing on Treatment Outcomes in Intermediate-Risk Pulmonary Embolism: A PEERLESS Randomized Controlled Trial Post Hoc Analysis
- Open Access
- 18 September 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (9) , 521
Predicting Tumor Recurrence with Early 18F-FDG PET-CT After Thermal and Non-Thermal Ablation
The purpose was to determine the ability of 18-fluorodeoxyglucose (18F-FDG) positron emission tomography–computed tomography (PET-CT) scans performed within 24 h of percutaneous image-guided ablation of primary and metastatic malignancies to predict ablation effectiveness and local tumor progression (LTP). This single-center retrospective review included patients who underwent image guided ablation (microwave ablation (MWA), cryoablation, or irreversible electroporation (IRE)) between August 2018 and February 2024 for primary and metastatic malignancies. The primary outcome measure encompassed correlating post-ablation 18F-FDG PET-CT findings with LTP development per tumor, assessed using the chi-square test. The secondary outcome measure was local tumor progression-free survival (LTPFS) per tumor, evaluated using the Kaplan–Meier survival curves, and potential confounders were identified in multivariable analysis utilizing Cox proportional hazards regression models. A total of 132 patients, who underwent 159 procedures for 224 tumors, were included. During follow-up, LTP developed in 120 out of 224 tumors (53.6%). The presence of residual nodular 18F-FDG avidity on PET-CT within 24 h after the ablation significantly correlated with the development of LTP at follow-up imaging (p < 0.001). The positive predictive value of nodular 18F-FDG avidity was 86.7%. In multivariable analysis, the hazard ratio (HR) for 18F-FDG avidity was 2.355 (95% CI 1.614–2.647; p < 0.001). The presence of 18F-FDG avidity on PET-CT within 24 h after the ablation was highly correlated with development of LTP and decreased LTPFS. The detection of residual tumor tissue may allow early re-treatments, especially in tumors with nodular uptake, contributing to increased LTPFS.
- 18 September 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (9) , 521
Open AccessPredicting Tumor Recurrence with Early 18F-FDG PET-CT After Thermal and Non-Thermal Ablation
The purpose was to determine the ability of 18-fluorodeoxyglucose (18F-FDG) positron emission tomography–computed tomography (PET-CT) scans performed within 24 h of percutaneous image-guided ablation of primary and metastatic malignancies to predict ablation effectiveness and local tumor progression (LTP). This single-center retrospective review included patients who underwent image guided ablation (microwave ablation (MWA), cryoablation, or irreversible electroporation (IRE)) between August 2018 and February 2024 for primary and metastatic malignancies. The primary outcome measure encompassed correlating post-ablation 18F-FDG PET-CT findings with LTP development per tumor, assessed using the chi-square test. The secondary outcome measure was local tumor progression-free survival (LTPFS) per tumor, evaluated using the Kaplan–Meier survival curves, and potential confounders were identified in multivariable analysis utilizing Cox proportional hazards regression models. A total of 132 patients, who underwent 159 procedures for 224 tumors, were included. During follow-up, LTP developed in 120 out of 224 tumors (53.6%). The presence of residual nodular 18F-FDG avidity on PET-CT within 24 h after the ablation significantly correlated with the development of LTP at follow-up imaging (p < 0.001). The positive predictive value of nodular 18F-FDG avidity was 86.7%. In multivariable analysis, the hazard ratio (HR) for 18F-FDG avidity was 2.355 (95% CI 1.614–2.647; p < 0.001). The presence of 18F-FDG avidity on PET-CT within 24 h after the ablation was highly correlated with development of LTP and decreased LTPFS. The detection of residual tumor tissue may allow early re-treatments, especially in tumors with nodular uptake, contributing to increased LTPFS.